Clinical Trial: NCT05582499
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | Fudan University |
| Information Provided By: | Fudan University |
| Last Update Posted: | 2026-05-28 |
Study Overview
Brief Summary
The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.
Official Title
Conditions
Intervention / Treatment
- Drug: Dalpiciclib
- Drug: Pyrotinib
- Drug: SHR-A1811
- Drug: SHR-1316
- Drug: Camrelizumab
- Drug: SHR-A1921
- Drug: Pertuzumab
- Drug: Trastuzumab
- Drug: Goserelin
- Drug: Letrozole
- Drug: Nab paclitaxel
- Drug: Carboplatin
- Drug: Epirubicin
- Drug: Cyclophosphamide
- Drug: Fluzoparib
- Drug: Apatinib
- Drug: Famitinib
- Drug: HB1801
- Drug: LEM
- Drug: TQB2102
- Drug: Benmelstobart
- Drug: Anlotinib
- Drug: TQB2868
- Drug: Ivonescimab
- Drug: JS207
- Drug: JSKN003
- Drug: HRS-4508
- Drug: SHR-4602
- Drug: paclitaxel
- Drug: HRS-6209
- Drug: 9MW2821
- Drug: IBI354
- Radiation: Stereotactic Body Radiation Therapy (SBRT)
Other Study ID Numbers
- FASCINATE-N
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Fudan University |
| Information Provided By: | Fudan University |
| Last Update Posted: | 2026-05-28 |
Study Overview
Brief Summary
The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.
Official Title
Conditions
Intervention / Treatment
- Drug: Dalpiciclib
- Drug: Pyrotinib
- Drug: SHR-A1811
- Drug: SHR-1316
- Drug: Camrelizumab
- Drug: SHR-A1921
- Drug: Pertuzumab
- Drug: Trastuzumab
- Drug: Goserelin
- Drug: Letrozole
- Drug: Nab paclitaxel
- Drug: Carboplatin
- Drug: Epirubicin
- Drug: Cyclophosphamide
- Drug: Fluzoparib
- Drug: Apatinib
- Drug: Famitinib
- Drug: HB1801
- Drug: LEM
- Drug: TQB2102
- Drug: Benmelstobart
- Drug: Anlotinib
- Drug: TQB2868
- Drug: Ivonescimab
- Drug: JS207
- Drug: JSKN003
- Drug: HRS-4508
- Drug: SHR-4602
- Drug: paclitaxel
- Drug: HRS-6209
- Drug: 9MW2821
- Drug: IBI354
- Radiation: Stereotactic Body Radiation Therapy (SBRT)
Other Study ID Numbers
- FASCINATE-N